We are live on ! Find out more
BLCM

Bellicum Pharmaceuticals, Inc.

Delisted

BLCM was delisted on the 1st of June, 2023.

29 hedge funds and large institutions have $7.09M invested in Bellicum Pharmaceuticals, Inc. in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 12 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,193% more call options, than puts

Call options by funds: $2.41M | Put options by funds: $105K

43% less funds holding

Funds holding: 5129 (-22)

58% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 12

69% less capital invested

Capital invested by funds: $22.6M → $7.09M (-$15.5M)

74% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 27

Holders
29
Holders Change
-22
Holders Change %
-43.14%
% of All Funds
0.64%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
5
Reduced
12
Closed
27
Calls
$2.41M
Puts
$105K
Net Calls
+$2.3M
Net Calls Change
+$2.02M
Name Holding Trade Value Shares
Change
Change in
Stake
BNP Paribas Financial Markets
51
BNP Paribas Financial Markets
France
-$204 -16 Closed
II
52
Inspire Investing
Idaho
+$311 +29 New

BLCM Hedge Fund Activity: Q1 2020 in Review

29 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q1 2020, worth a combined $7.09M — down 69% from $22.6M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of BLCM and 7 opened new positions — a net loss of 20 holders — while 12 trimmed existing stakes and 5 added.

The largest buyer was Sabby Management, opening a new position worth an estimated $203K. The largest seller was Principal Financial Group, exiting entirely with an estimated $649K sold.

  • 29 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q1 2020, down from 51 in Q4 2019.
  • Funds reported $7.09M of Bellicum Pharmaceuticals, Inc. stock for Q1 2020, down 69% quarter-over-quarter.
  • 7 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q1 2020 and 27 closed out, a net change of -20 holders.
  • The largest Bellicum Pharmaceuticals, Inc. buyer in Q1 2020 was Sabby Management, an estimated $203K added.
  • The largest Bellicum Pharmaceuticals, Inc. seller in Q1 2020 was Principal Financial Group, an estimated $649K sold.

Based on aggregated 13F filings for Q1 2020.